XETRA · MRK.DE
Merck KGaA
€150.30+€4.25 (+2.91%)
Merck KGaA’s quoted price sits in the upper half of its reported 52-week range, 0.86% below the high.
Loading market information…
XETRA · AFX.DE · EUR
Stock price, dividends, earnings
Quote as of Oct 29, 2026, 04:35 PM UTC. Cached market data; not a live quote.
One-year closing-price history · EUR. Historical prices are not a forecast.
Carl Zeiss Meditec AG’s quoted price sits in the upper half of its reported 52-week range, 25.31% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
THE INCOME SIDE
Carl Zeiss Meditec AG’s forward annual dividend is €0.55 per share, paid annual. The forward yield is 1.58% at the quoted price. Future payments can change.
Historical amounts are adjusted for stock splits. Understand ex-dividend and payment dates →
BEHIND THE RESULTS
Carl Zeiss Meditec AG’s next earnings report is currently expected on Dec 10, 2026, with estimated earnings per share of €0.48. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow Carl Zeiss Meditec AG’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Carl Zeiss Meditec AG operates as a medical technology company in Germany, rest of Europe, North America, and Asia. It operates in two segments, Ophthalmology and Microsurgery. The Ophthalmology segment offers products and solutions for the diagnosis and treatment of chronic eye diseases, including slit lamps, refractometers, and tonometers; optical coherence tomography and fundus cameras for retina examination; functional glaucoma diagnostic devices (perimeters); surgical ophthalmology products comprising surgical microscopes, biometers, and phacoemulsification and vitrectomy equipment; intraocular lenses for cataract surgery; and systems and consumables for laser eye surgery that include the VISUMAX femtosecond laser, which enables minimally invasive correction of vision defects using lenticular extraction, as well as digital products for the storage, analysis, and sharing of clinical data. The Microsurgery segment provides products and solutions for minimally invasive surgical treatments, including surgical visualization, interoperative radiotherapy, interoperative pathology, special surgical instruments, and digital solutions, as well as the ZEISS Tumor Workflow, a cross-product workflow solution. It serves physicians in various fields and hospitals. The company was founded in 1846 and is headquartered in Jena, Germany. Carl Zeiss Meditec AG operates as a subsidiary of ZEISS Group.
Latest available per-share figures in EUR. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 01:11 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
Completed calendar years and any current-year payments shown separately. Current-year totals are incomplete until all payments are made.
See annual income at the current dividend rate.
Assumes the annual dividend stays unchanged. Payments follow the company’s schedule. Excludes taxes, fees and currency changes.
| Q2 2025 | May 13, 2025 | €0.52+11.18% vs estimate | €560.02M+6.02% vs estimate |
|---|
| Q1 2025 | Feb 12, 2025 | €0.18-84.07% vs estimate | €490.50M-7.57% vs estimate |
|---|
| Q4 2024 | Dec 11, 2024 | €0.70+35.92% vs estimate | €579.63M-2.16% vs estimate |
|---|
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
€150.30+€4.25 (+2.91%)
Merck KGaA’s quoted price sits in the upper half of its reported 52-week range, 0.86% below the high.
€42.89+€0.30 (+0.7%)
Siemens Healthineers AG’s quoted price sits in the upper half of its reported 52-week range, 13.7% below the high.
€47.96+€1.93 (+4.19%)
Bayer Aktiengesellschaft’s quoted price sits in the upper half of its reported 52-week range, 11.05% below the high.
MX$953.08MX$0.00 (0.0%)
Bayer AG’s quoted price sits in the upper half of its reported 52-week range, 5.56% below the high.
€47.00+€0.67 (+1.44%)
Fresenius SE & Co. KGaA’s quoted price sits in the upper half of its reported 52-week range, 11.25% below the high.
€77.90+€0.45 (+0.58%)
BioNTech SE’s quoted price sits in the lower half of its reported 52-week range, 26.3% below the high.
€105.40+€0.80 (+0.76%)
Drägerwerk AG & Co. KGaA’s quoted price sits in the upper half of its reported 52-week range, 15.95% below the high.
€22.75-€0.15 (-0.66%)
Stratec SE’s quoted price sits in the upper half of its reported 52-week range, 14.31% below the high.
